2019
Retrospective Association Analysis of Longitudinal Binary Traits Identifies Important Loci and Pathways in Cocaine Use
Wu W, Wang Z, Xu K, Zhang X, Amei A, Gelernter J, Zhao H, Justice AC, Wang Z. Retrospective Association Analysis of Longitudinal Binary Traits Identifies Important Loci and Pathways in Cocaine Use. Genetics 2019, 213: 1225-1236. PMID: 31591132, PMCID: PMC6893384, DOI: 10.1534/genetics.119.302598.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesAssociation analysisGenome-wide association analysisCase-control genome-wide association studyPhenotype model misspecificationImportant locusGenetic architectureComplex traitsGenetic association analysisGene mappingGenome scanPathway analysisAssociation studiesAxonal guidanceGenetic variantsBinary traitsAssociation TestElectronic health record-based studiesPathwayImportant pathwayLociTraitsPhenotype distributionLongitudinal phenotypesPhenotype
2010
Patterns of drug use and abuse among aging adults with and without HIV: A latent class analysis of a US Veteran cohort
Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, Gordon AJ, Maisto SA, Day NL, Bryant K, Fiellin DA, Justice AC. Patterns of drug use and abuse among aging adults with and without HIV: A latent class analysis of a US Veteran cohort. Drug And Alcohol Dependence 2010, 110: 208-220. PMID: 20395074, PMCID: PMC3087206, DOI: 10.1016/j.drugalcdep.2010.02.020.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyHIV statusMultidrug usersDrug useLatent class analysisUS Veteran cohortAging Cohort StudyActive drug useSelf-reported drug useMental health disordersProblem of obesityElectronic medical recordsUninfected veteransCohort studyClinical variablesDrug use consequencesSocio-demographic covariatesMedical recordsHigh prevalenceUninfected adultsAge 50HIVHealth disordersDrug usersVeteran cohortEvaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value?
Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value? Value In Health 2010, 13: 535-542. PMID: 20345544, PMCID: PMC3032536, DOI: 10.1111/j.1524-4733.2010.00714.x.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionNonadherent patientsAdherence interventionsRelative riskRisk factorsAntiretroviral therapy adherence interventionsEffect sizeNonadherence risk factorsBehavioral risk factorsHIV careAntiretroviral adherencePatientsNonadherenceSocietal perspectiveIncremental costIntervention costsSmall effect sizesLife expectancyInterventionRisk reductionPlausible effect sizesCan Broader Diffusion of Value-Based Insurance Design Increase Benefits from US Health Care without Increasing Costs? Evidence from a Computer Simulation Model
Braithwaite RS, Omokaro C, Justice AC, Nucifora K, Roberts MS. Can Broader Diffusion of Value-Based Insurance Design Increase Benefits from US Health Care without Increasing Costs? Evidence from a Computer Simulation Model. PLOS Medicine 2010, 7: e1000234. PMID: 20169114, PMCID: PMC2821897, DOI: 10.1371/journal.pmed.1000234.Peer-Reviewed Original Research
2009
Do Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence?
Braithwaite RS, Roberts MS, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Nucifora K, Justice AC. Do Benefits of Earlier Antiretroviral Treatment Initiation Outweigh Harms for Individuals at Risk for Poor Adherence? Clinical Infectious Diseases 2009, 48: 822-826. PMID: 19210173, PMCID: PMC3032571, DOI: 10.1086/596768.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsComputer SimulationHIV InfectionsHumansLife ExpectancyMedication AdherenceMiddle AgedTime FactorsTreatment Outcome
2008
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Annals Of Internal Medicine 2008, 148: 178-85. PMID: 18252681, PMCID: PMC3124094, DOI: 10.7326/0003-4819-148-3-200802050-00004.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral loadHIV treatmentEarly treatmentEarly initiationLife expectancyVeterans Aging Cohort StudyChronic HIV infectionCombination antiretroviral therapyEarly treatment initiationAging Cohort StudyTherapy-related toxicityAge 40 yearsQuality-adjusted life expectancyAge 30 yearsBase-case analysisCohort studyHIV infectionTreatment initiationCopies/Current recommendationsLate treatmentImportant harmsTherapyTreatment
2007
Incorporating quality of evidence into decision analytic modeling.
Braithwaite RS, Roberts MS, Justice AC. Incorporating quality of evidence into decision analytic modeling. Annals Of Internal Medicine 2007, 146: 133-41. PMID: 17227937, PMCID: PMC3460380, DOI: 10.7326/0003-4819-146-2-200701160-00008.Peer-Reviewed Original Research
2006
Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation
Braithwaite RS, Shechter S, Roberts MS, Schaefer A, Bangsberg DR, Harrigan PR, Justice AC. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. Journal Of Antimicrobial Chemotherapy 2006, 58: 1036-1043. PMID: 17023498, DOI: 10.1093/jac/dkl386.Peer-Reviewed Original Research
2005
Estimating the proportion of patients infected with HIV who will die of comorbid diseases
Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. The American Journal Of Medicine 2005, 118: 890-898. PMID: 16084183, DOI: 10.1016/j.amjmed.2004.12.034.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusComorbid diseasesCombination therapyNaïve human immunodeficiency virusNon-HIV mortalityEffective antiretroviral therapyCells/mm3Proportion of patientsSeparate patient cohortsCopies/mLProportion of deathsLikelihood of deathAntiretroviral therapyObservational cohortHIV infectionTreatment failureViral loadImmunodeficiency virusMean agePatient cohortPatientsSubsequent deathPhenotypic resistanceTherapyCohort
2003
Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era
King JT, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Medical Decision Making 2003, 23: 9-20. PMID: 12583451, DOI: 10.1177/0272989x02239652.Peer-Reviewed Original ResearchConceptsCells/mm3Long-term survivalCD4 cell countAge-associated mortalityTreatment failureHIV/AIDSUS life tablesCell countActive antiretroviral therapy (HAART) eraBaseline CD4 cell countHIV/AIDS patientsLong-term survival dataShort-term survival dataAntiretroviral therapy eraPre-HAART cohortTreatment mortality rateActive antiretroviral therapyTreatment failure rateRisk of mortalitySurvival dataShort-term survivalHAART failureTherapy eraAntiretroviral therapyObservational cohort